Interferon induced transmembrane proteins (IFITMs) inhibit the cellular entry of a broad range of viruses, 1 4
IFITMs inhibit HIV-1 protein synthesis
IFITMs inhibit HIV-1 protein synthesis 1 3 7 uptake of virus occurs at a lower rate in primary CD4 + T-cells 32 . We confirmed that viral uptake was 1 3 8 minimally impeded with these during IFITM knockdown ( Figure 4D and E), consistent with prior 1 3 9 observations 28 . Therefore reductions in virus production were considered to arise predominantly from 1 4 0 IFITM-driven effects other than inhibition of viral entry. As such knockdown of IFITM2 led to a clear IFITM1 and IFITM2 expression lead to a more potent block in viral production than for IFITM3. Thus To better understand how IFITM proteins help suppressing viral translation, we explored the possibility 1 8 5 that they may be involved in a process that is able to distinguish viral RNA from cellular RNA. To 1 8 6 address this, we measured the level of unspliced viral RNA transcripts in the polysome fraction of 1 8 7
HEK293T cells transfected with a codon-optimized vector for HIV-1 NL4-3 Gag only 33 in conjunction virus produced was inhibited 18-fold by IFITM1, 21-fold by IFITM2 and 5-fold for IFITM3, suggesting a 2 2 9 4-fold enhancement of virus production due to HIV-1 Nef during IFITM1 and IFITM2 expression ( Figure   2 3 0 7A). We confirmed a significant reduction in HIV-1 Gag (p55) levels in cells producing nef-deleted virus 2 3 1 while IFITMs are expressed ( Figure 7B, S4B ), indicating that Nef may rescue the translational 2 3 2 suppression driven by IFITMs. As these data were generated through transfection, they were independent 2 3 3 of any influence of Nef upon viral entry 7, 8 . It is also of note that exogenous IFITM levels were not 2 3 4
reduced by HIV-1 Nef, perhaps indicating that antagonism of IFITM proteins may not occur via 2 3 5 degradation ( Figure 7B ).
3 6
We next investigated if Nef presented an advantage to viral growth in infected T-cells. We infected 2 3 7
SupT1 cells with either wild type or nef-deleted NL4-3 virus by post-entry induction of IFITM expression 2 3 8 via doxycycline ( Figure 7C ). As nef-deleted virus has an inherent growth defect, we normalized the 2 3 9 quantity of wild type and nef-deleted virus produced from IFITM-induced cells to vector control cells. We 2 4 0 chose to induce IFITMs after X4-tropic HIV-1 NL4-3 entry and limit infections to a single round through 2 4 1 the use of the CXCR4 antagonist AMD3100 after infection to mitigate the influence of IFITMs upon viral 2 4 2 entry. In this regard, we found that nef-deleted virus was no more susceptible to IFITM-mediated 2 4 3 restriction of entry than wild type virus ( Figure S4A ). Compared to wild type virus, production of nef-2 4 4 deleted virus in infected SupT1 cells was reduced significantly during IFITM expression, surprisingly 2 4 5 IFITM3 showed the greatest degree of rescue in SupT1 cells ( Figure 7C ), in contrast to data for 2 4 6 transfected 293T cells ( Figure 7A and B).
4 7
To further confirm the role of IFITM1 in suppressing virus production in T cells, we monitored the 2 4 8 production of either wild type or nef-deleted HIV-1 NL4-3 virus in multiple cycle infections in a C8166 2 4 9
T-cell line transduced to constitutively over-express IFITM1. As IFITM1 does not typically affect the 2 5 0 entry of CXCR4-tropic virus such as NL4-3 ( Figure 4A , B and 10,28 ), any difference in replication 2 5 1 measured between wild type and nef-deleted virus could only arise from IFITM1-mediated effects on 2 5 2 viral production, not cell entry. Therefore this experiment was not pursued for IFITM2 and IFITM3, as 2 5 3 their constitutive expression would inhibit NL4-3 virus entry and complicate interpretation. We found that 2 5 4
in the presence of IFITM1, the growth of nef-deleted virus was significantly reduced relative to wild type 2 5 5 virus, with wild type virus showing 2-fold inhibition at 5 days post-infection, while nef-deleted virus was 2 5 6
inhibited 5-fold by IFITM1 ( Figure 7D ). As wild type and nef-deleted virus data in C8166 cells were 2 5 7
individually normalized to the same viruses in C8166 vector control cells, the differences observed are 2 5 8 not likely due to Nef overcoming SERINC3/5 expression 7,8 , as these factors would be similarly present in 2 5 9 both cell lines. Interestingly, the benefit of Nef expression in the context of IFITM1 was lost in the later 2 6 0 stages of viral culture, when cell-to-cell infection typically predominates 42 . As nef-deleted virus was no 2 6 1 more susceptible to IFITM-mediated restriction of entry than wild type virus ( Figure S4A ), these findings 2 6 2 are only due to the influence of Nef to partially rescue virus production as seen in 293T cell transfections We then investigated if Nef from other lentiviruses was able to overcome IFITM-mediated inhibition of 2 6 5 protein synthesis using an HIV-1 NL4-3 plasmid proviral DNA into which lentiviral nef alleles had been 2 6 6 substituted 43 . The level of virus production for HIV-1 NL4-3 bearing other nef alleles during IFITM 2 6 7 expression was generally comparable to levels for wild type NL4-3 nef ( Figure 7E ), indicating that ability 2 6 8 of lentiviral Nef proteins to overcome IFITM mediated restriction of virus production is common.
6 9
To further confirm the role of Nef in antagonizing IFITMs, we titrated a plasmid bearing NA7 nef into 2 7 0 cells transfected with IFITM expression plasmids and nef-deleted NL4-3 proviral HIV-1 DNA. Nef 2 7 1 expression in trans rescued viral production from IFITM-mediated inhibition in a dose dependent manner 2 7 2 ( Figure 7F ). However, we note overexpression of Nef in cells transfected with 0.5μg Nef-encoding 2 7 3 plasmid resulted in a overall lower level of viral proteins compared with cells expressing lower levels of 2 7 4
Nef. Interestingly, increased Nef levels helped restore viral production in the context of IFITM expression 2 7 5 ( Figure 7F ), this rescue was not reflected in viral protein production levels ( Figure 7G and S4C), implying that the ability of Nef to rescue HIV production during IFITM expression does not occur at the 2 7 7 level of protein synthesis. In summary, these data show that Nef can help overcome IFITM-mediated 2 7 8 inhibition of HIV-1 production in a concentration-dependent manner. Taken together, our data demonstrate that HIV-1 Nef is able to help overcome the inhibition of viral protein production exerted by 2 8 0 IFITM proteins and therefore enhance infection. We report here that IFITM protein restrict HIV-1 by excluding viral mRNA from polysomes thereby and infectivity, there have been data suggesting that there may be a distinct IFITM function directed 2 8 8 towards HIV-1 production 10, 12, 14, 15, [22] [23] [24] [25] [26] . Despite the relative frequency of these passing observations on 2 8 9 viral production, the underlying processes leading to loss of viral production during IFITM expression 2 9 0
have not been explored. We have demonstrated the breadth of the IFITM-mediated restriction of virus production, identified the 2 9 2 viral replication process that is subverted, and determined a means by which HIV-1 may partially 2 9 3 overcome this effect. In addition, we find that restriction of viral production by IFITM proteins is clear 2 9 4
contributor towards the inhibition of HIV-1 production seen in cells exposed to type I interferon, and have 2 9 5 also shown that inhibition occurs in primary CD4 + T-cells at physiologically relevant levels of 2 9 6 endogenous IFITM expression. From a mechanistic perspective we have shown that HIV-1 RNA is the 2 9 7 target of this inhibition, though the viral determinant remains elusive. We therefore propose that 2 9 8
inhibition of viral protein synthesis is a genuine antiviral function exerted by IFITM proteins that is 2 9 9 distinct from previously described effects upon entry and infectivity. Initial suggestions of a late-stage IFITM-mediated restriction have typically surrounded two common 3 0 1 laboratory HIV-1 strains, NL4-3 and BH10 10, 12, 14, 25, 26 . However, for the putative anti-HIV restriction 3 0 2 factor viperin/RSAD2, analysis demonstrated that the phenotype could not be replicated beyond the 3 0 3 laboratory strain NL4-3 44 . Therefore our demonstration that IFITM proteins restrict production of 3 0 4 multiple HIV-1, HIV-2 and SIVs implies the phenotype we observe is likely not an artefact. This is HIV-1 production as occurs with human IFITM1. 3 0 7
The general mechanism of restriction we outline is specific exclusion of HIV-1 mRNA from polysomes 3 0 8 during IFITM expression. In HEK293T cells the effect principally occurs with IFITM1 and IFITM2, but in SupT1 cells showed an equivalent antiviral effect to IFITM1 and IFITM2, though, and this was also 3 1 1 linked to viral protein loss and was independent of IFITM-driven effects on viral entry. We consider that NFkB translocation) might also account for variation in antiviral activity between cell lines, as higher 3 1 9
virus transcriptional activity may overcome inhibition. However, it is important to note that we were able 3 2 0
to clearly confirm the inhibition of viral production in primary human CD4 + T-cells by IFITM2 and 3 2 1 IFITM1-3, demonstrating that inhibition of viral production by IFITMs occurs in HIV-1 target cells at 3 2 2 physiologically relevant levels of endogenously expressed IFITM proteins.
2 3
Why IFITM1 and IFITM2 should act similarly in many instances, when IFITM2 and IFITM3 have closer
amino acid sequence identity and display greater overlap in cellular localization is not yet clear 10, 19, 46, 47 . we anticipate the inhibition of protein synthesis to be similar 45, 46, 48 . This is pertinent for differences we 3 2 7
find between IFITM2 and IFITM3. Despite their high sequence similarity, they typically show distinct The exclusion of viral transcripts from polysomes mainly seemed to mainly affect unspliced and singly-spliced transcripts from polysome fractions, coupled with multiply-spliced transcript enrichment in low 3 3 2 sucrose fractions. This is perhaps indicative of some degree of multiply-spliced transcript translational 3 3 3 blockage that explains the loss of Nef protein seen throughout our experiments.
4
We saw no change in total unspliced mRNA levels in IFITM expressing cells yet there was modest 3 3 5 depletion of singly-spliced and multiply-spliced mRNA during IFITM1 and IFITM2 expression. Though 3 3 6
this overall depletion of total viral mRNA levels may partially account for some loss of Vpu and Nef 3 3 7
production, polysome analysis additionally demonstrated clear exclusion of these transcript classes from 3 3 8
translation. Why these overall mRNA levels should be reduced is of interest. One possibility is a 3 3 9
transcriptional inhibition or pre-translational degradation, but degradation of mRNAs that have been
inhibited in translation is thought to be common 49 . For example, the antiviral protein ZAP, which 3 4 1
degrades retroviral mRNA has also been shown to stall translation prior to mRNA degradation, 3 4 2 illustrating the fluid link between translational stalling and mRNA stability 50,51 .
4 3
Susceptibility to inhibition occurred at the level of viral mRNA and we so sought to identify a viral RNA of protein synthesis may be similarly obscure 56 . However, we were able to exclude the broader 3 5 6 possibility of general translational arrest via IFITM expression. Other aspects of the mechanism remain 3 5 7
shifts towards a cell-to-cell mode in later stages 42 . It has been proposed that this represents a means of seems to be a recurring weak point in replication strategy that the innate immune system has frequently 3 9 0 evolved to target. For example, PKR senses viral double stranded RNA and halts translation 65 , while 3 9 1
Schlaffen 11 inhibits viral protein production by disrupting tRNA synthesis 66 , and finally the protein ZAP which induces viral mRNA degradation also stalls viral translation 51 .
3 9 3
The model we put forward wherein IFITM expression specifically disrupts viral mRNA translation may 3 9 4 be applicable to other targets. Conceptually, other self and non-self RNAs may be affected also. It is then 3 9 5
of interest that a recent report found that LINE-1 retrotransposon mobility could be inhibited by IFITM1 characterization will therefore identify the viral RNA determinant of susceptibility, and the breadth of Human pQCXIP IFITM1-3 plasmids bearing an N-terminal FLAG were previously described 58 . The viral 4 0 3 construct pBR4-3-eGFP-Nef, encoding for wild type HIV-1 NL4-3, pBR4-3-IeGFPΔNef, HIV-1 NA7, Antibodies, cells and antiviral compounds 4 1 2
The following antibodies were used to detect IFITMs: human IFITM1 (clone 5B5E2, Proteintech), London) using the human CD14 + and CD4 + T cell isolation kits, respectively, according to manufacturer instruction (Miltenyi Biotec). 0.5x10 6 /ml CD14 + monocytes were differentiated into macrophages with 4 2 5 100ng/ml GMCSF (Peprotech) at 2-3 days interval until day 7. CD4 + T cells were activated at 1x10 6 /ml 4 2 6
with T cell activator CD3/CD28 Dynabeads (ThermoFisher), at a bead-to-cell-ratio of 1:1, in complete Transfections HEK293T cells were plated at 2x10 4 /cm 2 in 48-well plates (for measurements of virus production), 6-well for 10 minutes at room temperature and then added to cells. Medium was replaced with medium 4 5 0 containing 5μM AMD3100 and 100IU/ml IFN-β (Peprotech) 4 hours post-transfection. AMD3100. C8166 cells were infected with the same protocol without AMD3100. Supernatant was 4 7 0 harvested at the indicated time-points after centrifugation at 500x g for 5 minutes at room temperature. In the presence of CD3/CD28 T-cell activator beads, 5x10 5 /ml activated CD4 + T cells were transduced and incubated for 30 minutes at room temperature before chemiluminiscence was read by a plate reader. for 30 minutes at room temperature and then incubated in streptavidin-coated microplates for 15 hours at Luciferase activity of infected TZM/bl cells was analyzed with Bright-Glo luciferase activity kit 5 0 7
following manufacturer instructions (Promega). Polysome analysis was performed with both manual fractionation and RNA analysis 69 . inhibitor cocktail (all from Sigma) and 800U/ml RNase OUT (ThermoFisher), for 10 minutes on ice. Cell 5 1 5
lysate was centrifuged at 10, 000x g for 1 minute at 4°C and supernatant was then adjusted to 200μg/ml 5 1 6
cycloheximide and 700μg/ml heparin (Sigma). Following centrifugation at 12, 000x g for 10 minutes at 5 1 7
4°C, an aliquot of supernatant was taken as input and the rest was layered onto a 10% to 50% sucrose 5 1 8 gradient prepared using polysomal buffer. Gradients were then ultracentrifuged at 300,000x g for 16 hours 5 1 9
at 4°C (Sorvall). After centrifugation, 20 550μl fractions were collected from the top of the gradients for samples were quantified against cloned standards.
3 4
Primers used to amplify unspliced (Forward, 5'-CCGTCTGTTGTGTGACTCTGG-3', reverse, 5'-5 3 5
GAGTCCTGCGTCGAGAGATCT-3'), multiply-spliced (Forward, 5'-CAGACTCATCAAGCTTCTCTATCAA-3', reverse, 5'-CTATTCCTTCGGGCCTGTC-3') and singly-5 3 7 spliced (Forward, 5'-TAATCGGCCGAACAGGGACTTGAAAGCGAAAG-3', reverse, 5'-5 3 8
CCCATCTCCACAAGTGCTGATACTTC-3') viral transcripts are described in 70 , 71 , and 72 , respectively.
3 9
Oligonucleotide probes are labelled with 5'-FAM and 3'-TAMRA, (unspliced, 5'- TCTTATTGGGCGCCTGGTCAC-3', as described in 71 . Immunoblotting 5 4 7
Cells were washed once with PBS and then lyzed in radioimmunoprecipitation buffer (RIPA, containing Cells were then infected with HIV-1 89.6 with equivalent p24 concentrations. Cells were pre-treated with 7 7 6 AMD3100 for 2 hours prior to infection and throughout. viral proteins in infected cells was analyzed by 7 7 7
immunoblotting. Immediately after infection, cells were treated with trypsin and washed with PBS before and the data normalized, fold change of virus production compared to vector control is indicated. 
